To validate RAD51 inhibition as an appropriate strategy to sensitize bCSCs to treatment such as cisplatin, we performed a preclinical assay using three breast cancer PDXs (CRCM434, CRCM404, and CRCM436) (Supplementary Fig. 6A). Here, RAD51 is linked to breast carcinoma.